Last reviewed 2026-08-25
No peptide is FDA-approved for building muscle in healthy adults. The class most often sold for it — growth hormone secretagogues — does raise growth hormone and IGF-1, but the controlled human research on growth hormone in healthy adults found that the lean mass it adds is substantially fluid rather than contractile tissue, and that strength did not reliably improve. If your goal is size and strength, the training and protein intake underneath matter more than any compound on this page.
Muscle growth is the single most searched goal on this site, and it is also the one where the gap between marketing and evidence is widest. Most peptides sold for it work, if they work at all, by raising your own growth hormone rather than by acting on muscle directly.
That distinction matters more than it sounds. Growth hormone reliably increases lean body mass as measured on a scale or by DEXA. But controlled research in healthy adults has repeatedly found that much of that gain is water retention and connective tissue rather than contractile muscle, and that measured strength does not improve in step with it. Body composition readouts move; what you can lift often does not.
That does not make these compounds useless or fraudulent. It means the honest claim is narrower than the one being sold, and that anyone spending several hundred dollars a month deserves to know which one they are buying.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| CJC-1295 | Limited human data | Research | $120–$350 |
| Ipamorelin | Limited human data | Research | $100–$300 |
| Sermorelin | No human evidence for this claim | Compounded | $150–$400 |
| Tesamorelin | Human trials, not approved for this use | FDA-approved | $300–$600 |
| GHRP-2 | Limited human data | Research | $80–$250 |
| GHRP-6 | Limited human data | Research | $80–$250 |
| Hexarelin | Limited human data | Research | Not published |
| IGF-1 LR3 | No human evidence for this claim | Research | Not published |
| BPC-157 | Animal studies only | Research | $100–$300 |
| MOTS-c | Animal studies only | Research | $200–$500 |
Growth hormone releasing hormone analogue; raises GH output over a longer window than natural GHRH.
The catch: Human studies confirm it raises GH and IGF-1. No controlled trial has shown it increases muscle mass or strength in healthy adults.
Selective GH secretagogue, usually stacked with CJC-1295 for a larger pulse.
The catch: Selective for GH release without the cortisol and prolactin rise seen with older GHRPs, which is a real advantage — but selectivity is not the same as a demonstrated muscle benefit.
GHRH analogue that stimulates the pituitary to release GH.
The catch: Approved as Geref for paediatric growth hormone deficiency and withdrawn from the US market in 2008; it is now supplied by compounding pharmacies. There is no evidence it builds muscle in healthy adults.
GHRH analogue with the strongest clinical dataset of any compound on this page.
The catch: FDA-approved, but for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. That approval says nothing about muscle growth in healthy people, and the studied population is not comparable.
Older growth hormone releasing peptide, potent GH stimulus.
The catch: Raises GH, but also raises cortisol and prolactin, which is why more selective agents largely replaced it. No muscle outcome data in healthy adults.
Older GH secretagogue, notable for a strong appetite increase.
The catch: The pronounced hunger it causes is often the most noticeable effect. Same cortisol and prolactin caveat as GHRP-2, and no muscle outcome data.
Potent GH secretagogue in the GHRP family.
The catch: Its GH response is documented to attenuate with continued administration, so the effect that is being paid for diminishes over a course.
Modified IGF-1 sold on the premise of acting directly on muscle tissue.
The catch: Developed as a cell culture reagent, not a therapeutic, and never tested in humans for this. Hypoglycaemia is a genuine acute risk, and IGF-1 signalling promotes cell proliferation generally.
Used alongside training for soft tissue recovery rather than growth itself.
The catch: Essentially all of the healing data is in rodents. It is not a muscle builder, and is included here only because it is commonly stacked for training recovery.
Mitochondrial-derived peptide studied for metabolic and exercise capacity effects.
The catch: Interesting exercise-mimetic findings in mice. Human data on performance or muscle mass is absent.
Nothing here has good human evidence for building muscle in a healthy trained adult. Tesamorelin has the strongest data of any compound on this page, but it was studied for reducing visceral fat in HIV-associated lipodystrophy — a different population and a different outcome.
Combinations people actually run, with the dosing protocol and the evidence framing each one deserves. These are community protocols rather than tested regimens.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
Sermorelin requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
There is no peptide with good human evidence for building muscle in healthy adults. The most commonly used combination is CJC-1295 with ipamorelin, which reliably raises growth hormone and IGF-1 — but raising those hormones has not been shown in controlled research to produce meaningful gains in strength or contractile muscle in people who are not growth hormone deficient.
They increase lean body mass as measured by scale weight or DEXA. Controlled studies of growth hormone in healthy adults found that a substantial part of that increase is fluid retention and connective tissue rather than contractile muscle, and that strength did not improve proportionally. The number on the body composition readout moves more than performance does.
Most are not approved by the FDA for any use and are sold either as research chemicals or through compounding pharmacies. They are also banned by WADA and by most drug-tested sporting bodies, including growth hormone secretagogues and IGF-1 analogues. Competing athletes should assume every compound on this page will cause a failed test.
BPC-157 is not a muscle builder. It is used for soft tissue recovery, and even that rests almost entirely on rodent studies rather than human trials. It appears on muscle-growth stacks because faster recovery is thought to allow more training volume, not because it acts on muscle.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory